Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer
PHASE1CompletedINTERVENTIONAL
Enrollment
56
Participants
Timeline
Start Date
October 31, 2012
Primary Completion Date
January 31, 2015
Study Completion Date
January 31, 2015
Conditions
Cancer
Interventions
DRUG
REGN1400
DRUG
Erlotinib
DRUG
Cetuximab
Trial Locations (6)
Unknown
Santa Monica
Atlanta
Detroit
Buffalo
New York
San Antonio
All Listed Sponsors
lead
Regeneron Pharmaceuticals
INDUSTRY
NCT01727869 - Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer | Biotech Hunter | Biotech Hunter